Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
August 14, 2024 5:52 AM EDTGoldman Sachs analyst Richard Law reiterated a Buy rating and $29.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
The analyst comments "MLYS reported 2Q24 financial results on Tuesday with GAAP EPS of -$0.83. R&D expenses were $39.3M, and G&A were $5.9M. Cash/cash equivalents of ~$311M are expected to provide... More
Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
August 14, 2024 5:23 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $45.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).
The analyst comments "We reiterate our Buy on MLYS, $45 TP. MLYS is proceeding on all fronts to enroll a pivotal program that captures the most comprehensive set... More
